Total Funding
54
40
Total FundingPost-IPO Debt raised
Growth Score
-3 pts
Heat Score
-2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
140160
Gelesis is a biotechnology company developing first-in-class therapeutics to safely treat obese, overweight, and diabetic patients.
Torsten Winkler: Investor
Hassan M. Heshmati: Executive Vice President, Endocrinology and Metabolism
About the Company
Gelesis is a clinical stage biotechnology company developing first-in-class therapeutics to safely treat obese, overweight, and diabetic patients. Gelesis100, our lead product, is an orally- administered smart pill which is constructed of materials that are General Recognized as Safe (GRAS) by the Food and Drug Administration (FDA). Each Gelesis100
capsule contains thousands of hydrogel particles approximately the size of a grain of salt that expand to 100 times their dry weight. The pill is designed to act mechanically in the stomach and small intestine to increase satiety and decrease hunger, resulting in reduced caloric intake and weight loss. <a href="http://www.gelesis.com/">Gelesis</a> was founded in 2006 in Boston, Massachusetts
